{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:13Z","timestamp":1789749493575,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.det.2023.12.002","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T07:27:52Z","timestamp":1703834872000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatment of Pyoderma Gangrenosum"],"prefix":"10.1016","volume":"42","author":[{"given":"Marcus G.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav N.","family":"Tolkachjov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jid.2020.04.019","article-title":"Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum","volume":"141","author":"Haag","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"11","key":"10.1016\/j.det.2023.12.002_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16401","article-title":"The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum","volume":"180","author":"Jockenh\u00f6fer","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib5","unstructured":"Kamal K, Xia E, Li SJ, et al. Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum (PG) in Clinical Trials: A Delphi Consensus on Behalf of the Understanding PG: Review and Assessment of Disease Effects (UPGRADE) Group. J Invest Dermatol. 2023:S0022-202X(23)03193-7."},{"key":"10.1016\/j.det.2023.12.002_bib6","article-title":"Subjective assessments in pyoderma gangrenosum diagnostic frameworks undermine framework agreement","author":"Nusbaum","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib7","first-page":"ljad420","article-title":"A core domain set for pyoderma gangrenosum trial outcomes - an international e-Delphi and consensus study from the UPGRADE initiative","author":"Jacobson","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/exd.14534","article-title":"Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease","volume":"31","author":"Flora","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib9","doi-asserted-by":"crossref","first-page":"h2958","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.det.2023.12.002_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/bjd.15561","article-title":"Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial","volume":"177","author":"Mason","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2023.12.002_bib11","first-page":"3328","article-title":"Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum","volume":"23","author":"Abu-Elmagd","year":"1991","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00054725-200407000-00014","article-title":"Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis","volume":"10","author":"Baumgart","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.det.2023.12.002_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/adc.2004.063370","article-title":"Successful tacrolimus (FK506) therapy in a child with pyoderma gangrenosum","volume":"90","author":"Deckers-Kocken","year":"2005","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.det.2023.12.002_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/iwj.13067","article-title":"Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review","volume":"16","author":"Ben Abdallah","year":"2019","journal-title":"Int Wound J"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind, placebo-controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.det.2023.12.002_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaad.2016.06.016","article-title":"Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study","volume":"75","author":"Thomas","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Part 2","key":"10.1016\/j.det.2023.12.002_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/0190-9622(92)70200-Y","article-title":"Peristomal pyoderma gangrenosum","volume":"27","author":"Keltz","year":"1992","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/09546630903268239","article-title":"Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum","volume":"21","author":"Marzano","year":"2010","journal-title":"J\u00a0Dermatol Treat"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib19","first-page":"106","article-title":"Letter to the editor: Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum","volume":"7","author":"Wollina","year":"2013","journal-title":"J\u00a0Dermatol Case Rep"},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archdermatol.2009.326","article-title":"The Safety and Efficacy of Pimecrolimus, 1%, Cream for the Treatment of Netherton Syndrome: Results From an Exploratory Study","volume":"146","author":"Yan","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib21","unstructured":"Cecchi R, Pavesi M, Bartoli L, Brunetti L. Successful Treatment of Localized Pyoderma Gangrenosum with Topical Pimecrolimus. https:\/\/journals-sagepub-com.proxy.bib.uottawa.ca\/doi\/10.1177\/120347541201600503. Accessed September 8, 2023."},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1468-3083.2007.02280.x","article-title":"Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1","volume":"22","author":"Bellini","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.det.2023.12.002_bib23","first-page":"1058","article-title":"Efficacy of Systemic Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Review","volume":"17","author":"Din","year":"2018","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2013.05.028","article-title":"Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent","volume":"69","author":"Li","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2023.12.002_bib25","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/ijd.15539","article-title":"Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review","volume":"60","author":"Hrin","year":"2021","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/09546634.2018.1506083","article-title":"Biologic and small-molecule medications in the management of pyoderma gangrenosum","volume":"30","author":"McKenzie","year":"2019","journal-title":"J\u00a0Dermatol Treat"},{"issue":"5","key":"10.1016\/j.det.2023.12.002_bib27","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br J Dermatol"},{"issue":"10 Supplement","key":"10.1016\/j.det.2023.12.002_bib28","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.jid.2021.08.046","article-title":"044 Safety and efficacy of anti-IL-17 (Secukinumab) for the treatment of pyoderma gangrenosum","volume":"141","author":"Lauffer","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib29","article-title":"Pyoderma gangrenosum treated with secukinumab: A case report","volume":"8","author":"McPhie","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"11","key":"10.1016\/j.det.2023.12.002_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jdcr.2020.08.033","article-title":"Rapid resolution of pyoderma gangrenosum with brodalumab therapy","volume":"6","author":"Tee","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/ds.ds_40_20","article-title":"Use of brodalumab for the treatment of pyoderma gangrenosum: A case report","volume":"39","author":"Huang","year":"2021","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.det.2023.12.002_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdcr.2023.05.002","article-title":"Targeted therapy with ixekizumab in pyoderma gangrenosum: A case series and a literature overview","volume":"37","author":"Kao","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.det.2023.12.002_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jdcr.2020.06.011","article-title":"Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab","volume":"6","author":"Petty","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.det.2023.12.002_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjd.15850","article-title":"Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series","volume":"178","author":"Song","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1440-0960.2008.00506.x","article-title":"Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin","volume":"50","author":"De Zwaan","year":"2009","journal-title":"Australas J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2023.12.002_bib36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/09546634.2019.1606888","article-title":"Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum","volume":"31","author":"Haag","year":"2020","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib37","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/09546634.2021.1937475","article-title":"Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes","volume":"33","author":"Westerdahl","year":"2022","journal-title":"J\u00a0Dermatol Treat"},{"issue":"5","key":"10.1016\/j.det.2023.12.002_bib38","first-page":"e25177","article-title":"Management of idiopathic pyoderma gangrenosum with azathioprine as the primary adjunct in an asian man: a case report","volume":"14","author":"Nazir","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib39","first-page":"83","article-title":"Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine","volume":"24","author":"Chatzinasiou","year":"2016","journal-title":"Acta Dermatovenerol Croat ADC"},{"key":"10.1016\/j.det.2023.12.002_bib40","series-title":"Comprehensive dermatologic drug therapy","author":"Wolverton","year":"2020"},{"issue":"8956","key":"10.1016\/j.det.2023.12.002_bib41","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(95)90801-3","article-title":"Treatment of pyoderma gangrenosum with colchicine","volume":"345","author":"Paolini","year":"1995","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000079897","article-title":"Treatment of Pyoderma gangrenosum with Low-Dose Colchicine","volume":"209","author":"Kontochristopoulos","year":"2004","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2023.12.002_bib43","first-page":"466","article-title":"Pyoderma gangrenosum in a patient with psoriatic arthritis","volume":"14","author":"Spangler","year":"2001","journal-title":"J\u00a0Am Board Fam Pract"},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib44","first-page":"10560","article-title":"Pyoderma gangrenosum of the penis","volume":"28","author":"Loloi","year":"2021","journal-title":"Can J Urol"},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ijd.13740","article-title":"SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature","volume":"57","author":"Vekic","year":"2018","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2023.12.002_bib46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaad.2019.09.012","article-title":"Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review","volume":"82","author":"Wang","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2023.12.002_bib47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ced.13792","article-title":"Successful treatment of PAPA syndrome with minocycline, dapsone, deflazacort and methotrexate: a cost-effective therapy with a 2-year follow-up","volume":"44","author":"Sardana","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2023.12.002_bib48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/0378-6323.186497","article-title":"Intralesional methotrexate as an adjuvant treatment for pyoderma gangrenosum: A case report","volume":"83","author":"Del Puerto","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.det.2023.12.002_bib49","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib50","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0190-9622(98)70513-4","article-title":"Recalcitrant pyoderma gangrenosum: Treatment with thalidomide","volume":"38","author":"Hecker","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2023.12.002_bib51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4065\/75.8.842","article-title":"Recalcitrant Pyoderma Gangrenosum Treated With Thalidomide","volume":"75","author":"Federman","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.det.2023.12.002_bib52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2133.1998.02087.x","article-title":"Pyoderma gangrenosum of the penis","volume":"138","author":"Farrell","year":"1998","journal-title":"Br J Dermatol"},{"issue":"5, Part 1","key":"10.1016\/j.det.2023.12.002_bib53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0190-9622(08)80705-0","article-title":"Pyoderma gangrenosum associated with Beh\u00e7et\u2019s disease: Treatment with thalidomide","volume":"23","author":"Rustin","year":"1990","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib54","first-page":"61","article-title":"Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case","volume":"9","author":"Malkan","year":"2016","journal-title":"Int Med Case Rep J"},{"issue":"1","key":"10.1016\/j.det.2023.12.002_bib55","first-page":"67","article-title":"Pyoderma gangrenosum in a child. Treatment with thalidomide","volume":"29","author":"Venencie","year":"1982","journal-title":"Ann Pediatr (Paris)"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib56","doi-asserted-by":"crossref","first-page":"e12952","DOI":"10.1111\/dth.12952","article-title":"Penile pyoderma gangrenosum: Successful treatment with thalidomide","volume":"32","author":"Hu","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2023.12.002_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdcr.2020.12.005","article-title":"Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum","volume":"8","author":"Baier","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2023.12.002_bib58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdcr.2021.11.030","article-title":"Modified dose of guselkumab for treatment of pyoderma gangrenosum","volume":"21","author":"Reese","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib59","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/iwj.13359","article-title":"Successful treatment of a refractory pyoderma gangrenosum with risankizumab","volume":"17","author":"Burgdorf","year":"2020","journal-title":"Int Wound J"},{"key":"10.1016\/j.det.2023.12.002_bib60","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2147\/CCID.S374534","article-title":"Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report","volume":"15","author":"Leow","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"10.1016\/j.det.2023.12.002_bib61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/ajd.13196","article-title":"Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stone","volume":"61","author":"John","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2023.01.022","article-title":"Spesolimab use in treatment of pyoderma gangrenosum","volume":"34","author":"Gu\u00e9nin","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.det.2023.12.002_bib63","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.16676","article-title":"JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum","volume":"62","author":"Castro","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib64","doi-asserted-by":"crossref","first-page":"100099","DOI":"10.1016\/j.jtauto.2021.100099","article-title":"Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor","volume":"4","author":"Scheinberg","year":"2021","journal-title":"J\u00a0Transl Autoimmun"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib65","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jvc2.62","article-title":"Successful treatment of pyoderma gangrenosum with Janus kinase 1\/2 inhibition","volume":"1","author":"Sitaru","year":"2022","journal-title":"JEADV Clin Pract"},{"issue":"6","key":"10.1016\/j.det.2023.12.002_bib66","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/ced.14683","article-title":"Tofacitinib for the treatment of refractory pyoderma gangrenosum","volume":"46","author":"Orfaly","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2023.12.002_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2023.05.016","article-title":"Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib","volume":"37","author":"Van Eycken","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2023.12.002_bib68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdcr.2022.10.001","article-title":"Treatment of pyoderma gangrenosum with apremilast monotherapy","volume":"30","author":"Bordeaux","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.det.2023.12.002_bib69","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/1346-8138.15283","article-title":"Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn\u2019s disease","volume":"47","author":"Vernero","year":"2020","journal-title":"J\u00a0Dermatol"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib70","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2017.02.019","article-title":"Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum","volume":"3","author":"Laird","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.det.2023.12.002_bib71","doi-asserted-by":"crossref","first-page":"808","DOI":"10.12968\/jowc.2022.31.10.808","article-title":"Pyoderma gangrenosum and dehydrated human amnion\/chorion membrane: a potential tool for an orphan disease","volume":"31","author":"Alston","year":"2022","journal-title":"J\u00a0Wound Care"},{"issue":"4","key":"10.1016\/j.det.2023.12.002_bib72","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000481432","article-title":"Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients","volume":"233","author":"Kolios","year":"2017","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2023.12.002_bib73","doi-asserted-by":"crossref","first-page":"e13412","DOI":"10.1111\/dth.13412","article-title":"A\u00a0practical approach to the clinical management of pyoderma gangrenosum","volume":"33","author":"Janowska","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2023.12.002_bib74","doi-asserted-by":"crossref","first-page":"e922581","DOI":"10.12659\/AJCR.922581","article-title":"Negative Pressure Wound Therapy in Pyoderma Gangrenosum Treatment","volume":"21","author":"Bazali\u0144ski","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.det.2023.12.002_bib75","series-title":"StatPearls","article-title":"Pyoderma Gangrenosum","author":"Schmieder","year":"2023"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863523001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863523001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:48:00Z","timestamp":1760006880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863523001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0733863523001079"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2023.12.002","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Pyoderma Gangrenosum","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}